Phase I results of both IV and oral administration for CG-0255: a novel fast-acting antiplatelet drug with a new activation pathway

医学 药理学 药品 药品管理局 口服 内科学
作者
Xiaohong Chen,Haohao Yan,Fan Guo,Hong Wu,Kun Hou,Chen Lu,Xiaojun Tang,Weibin Fan,Junjie Chen,Yong Zhang,Zhen Gu,Dinh Son Ngoc Nguyen,Guo‐Wei He
出处
期刊:European Heart Journal [Oxford University Press]
卷期号:45 (Supplement_1)
标识
DOI:10.1093/eurheartj/ehae666.3343
摘要

Abstract Clopidogrel is an extremely widely used antiplatelet drug, but with serious shortcomings. It is a prodrug that depends critically on liver CYP oxidation enzyme CYP2C19 for activation to its active metabolite H4. However, large fractions of world population carry loss of function CYP2C19 alleles, ranging from a low ~21% in Latino to a strikingly high ~59% in east Asian population. Known as clopidogrel resistance, US FDA added a black box warning to clopidogrel label. Despite this issue, routine CYP2C19 screening for clopidogrel patients is not performed, putting many patients at risk. Clopidogrel is also slow to take effect and not amenable for IV formulation, limiting its clinical use in emergency. To overcome these issues, we have invented a novel antiplatelet drug CG-0255, which is the world’s first thioester prodrug with a new activation pathway. CG-0255 has been designed to require only abundantly present and widely distributed carboxylesterases for metabolizing to its active metabolite, which is identical to clopidogrel active metabolite H4 generated through CYP metabolism. Thus, CG-0255 completely bypasses the CYP metabolism and overcomes clopidogrel resistance. In addition, CG-0255 has a much faster onset of action and high solubility in water and has been formulated for both IV and oral administration. Here we report the results of an open label phase I study of CG-0255 oral tablets to assess safety, tolerability, pharmacodynamics (PK), and pharmacokinetics (PD: inhibition of platelet aggregation, IPA) in healthy volunteers. It was a single dose escalation study, 4 cohorts with 6 participants each given CG-0255 oral tablets at doses ranging from 2 to 10 mg. Clopidogrel was the positive control and given at 300 mg. Blood samples for PK/PD analysis were collected pre-dosing and at various time points post dosing. VerifyNow was used for IPA measurement. CG-0255 is generally safe and well tolerated. PK analysis shows fast and consistent conversion of CG-0255 to active metabolite H4. PD results indicate that CG-0255 IPA is dose-dependent, easily matching or surpassing that of clopidogrel 300 mg for all doses. At the highest 10 mg dose, CG-0255 IPA reaches over 90% in less than 30 minutes, well above that of clopidogrel. In addition, CG-0255 IPA shows minimum individual variations, and the antiplatelet effect is long lasting due to its irreversible binding to the P2Y12 receptor. These results are consistent with our earlier reported Phase I results for CG-0255 IV injection. In conclusion, CG-0255 is a novel, fast-acting and long-lasting antiplatelet drug. It shares identical metabolite H4 with clopidogrel but relies only on carboxylesterases for activation, overcoming the resistance and other issues associated CYP-based oxidation metabolism. As the only antiplatelet drug available for both IV and oral administrations, CG-0255 fills unmet medical needs and will greatly benefit patients and medical community.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
感谢sisisi转发科研通微信,获得积分50
刚刚
自由甜瓜完成签到,获得积分10
刚刚
任性的傲柏完成签到,获得积分0
刚刚
Eli发布了新的文献求助10
刚刚
00gi完成签到,获得积分10
刚刚
小冯1完成签到,获得积分10
1秒前
郑瑞完成签到 ,获得积分10
1秒前
清新的石头完成签到,获得积分10
1秒前
好好完成签到,获得积分10
1秒前
yygz0703完成签到 ,获得积分10
1秒前
梨恩完成签到,获得积分20
1秒前
丁丁当当完成签到,获得积分10
1秒前
hitech完成签到,获得积分10
2秒前
感谢selena转发科研通微信,获得积分50
2秒前
777完成签到 ,获得积分10
2秒前
阿拉丁发布了新的文献求助20
2秒前
谦让的鹏煊完成签到,获得积分10
3秒前
风随完成签到,获得积分10
3秒前
婉莹完成签到 ,获得积分0
3秒前
林慕然2023完成签到,获得积分10
3秒前
唠叨的访文完成签到,获得积分10
4秒前
hongtaoli2024完成签到 ,获得积分10
4秒前
感谢kinlo97转发科研通微信,获得积分50
4秒前
完美世界的应助被梨恩采纳,获得10
5秒前
只道寻常完成签到,获得积分10
6秒前
Lily完成签到,获得积分10
6秒前
封典完成签到,获得积分10
6秒前
感谢负责的代亦转发科研通微信,获得积分50
7秒前
zh完成签到 ,获得积分10
7秒前
7秒前
valiente完成签到,获得积分10
7秒前
wenli完成签到,获得积分10
7秒前
Bryant完成签到,获得积分10
8秒前
三脸茫然完成签到 ,获得积分0
8秒前
xxx完成签到 ,获得积分10
8秒前
StarXG完成签到,获得积分10
8秒前
9秒前
wqwq69完成签到,获得积分10
9秒前
9秒前
liliang316完成签到,获得积分10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173463
求助须知:如何正确求助?哪些是违规求助? 9565690
关于积分的说明 21781315
捐赠科研通 7767647
什么是DOI,文献DOI怎么找? 3431597
关于科研通互助平台的介绍 2555855
邀请新用户注册赠送积分活动 2476808